Trials / Terminated
TerminatedNCT02134080
FAAH Inhibitor Trial for Adults With Tourette Syndrome
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 5 (actual)
- Sponsor
- Yale University · Academic / Other
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this trial is to examine the safety, tolerability and feasibility in the use of a FAAH inhibitor for the treatment of adults with Tourette syndrome.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PF-04457845 | PF-04457845 will be administered orally at 4mg daily for four weeks. |
| DRUG | Placebo | Placebo will be administered orally at 4mg daily for four weeks. |
Timeline
- Start date
- 2014-05-01
- Primary completion
- 2017-03-01
- Completion
- 2017-03-01
- First posted
- 2014-05-08
- Last updated
- 2018-10-29
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02134080. Inclusion in this directory is not an endorsement.